Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)

This study aims to establish an ambispective cohort platform centered on the pathological axis of "sarcopenia-metabolic disorders-aging progression", integrating multimodal data including demographic characteristics, lifestyle factors, clinical phenotypes, laboratory tests, medical imaging, and biospecimens. Namely 'Sarcopenia, Metabolic Diseases, and Integrated Aging Longitudinal Evaluation (SMILE)'.

NCT Number	NCT07205510
Lead Sponsor	RenJi Hospital
Conditions	Sarcopenia, Metabolic Diseases, All-cause Mortality, Aging, Cardiometabolic Diseases
Enrollment	10,000 participants
Start Date	2020-12-01
Primary Completion	2040-12-31 (estimated)
Study Completion	2040-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-10-03